• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. Recent Advances in Manufacturing Innovative Stents
 
  • Details
  • Full
Options
2020
Journal Article
Title

Recent Advances in Manufacturing Innovative Stents

Abstract
Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, many research groups are focusing on designing new or improving existent stents. Since the beginning of the stent development in 1986, starting with bare-metal stents (BMS), these devices have been continuously enhanced by applying new materials, developing stent coatings based on inorganic and organic compounds including drugs, nanoparticles or biological components such as genes and cells, as well as adapting stent designs with different fabrication technologies. Drug eluting stents (DES) have been developed to overcome the main shortcomings of BMS or coated stents. Coatings are mainly applied to control biocompatibility, degradation rate, protein adsorption, and allow adequate endothelialization in order to ensure better clinical outcome of BMS, reducing restenosis and thrombosis. As coating materials (i) organic polymers: polyurethanes, poly(e- caprolactone), styrene-b-isobutylene-b-styrene, polyhydroxybutyrates, poly(lactide-co-glycolide), and phosphoryl choline; (ii) biological components: vascular endothelial growth factor (VEGF) and anti-CD34 antibody and (iii) inorganic coatings: noble metals, wide class of oxides, nitrides, silicide and carbide, hydroxyapatite, diamond-like carbon, and others are used. DES were developed to reduce the tissue hyperplasia and in-stent restenosis utilizing antiproliferative substances like paclitaxel, limus (siro-, zotaro-, evero-, bio-, amphi-, tacro-limus), ABT-578, tyrphostin AGL-2043, genes, etc. The innovative solutions aim at overcoming the main limitations of the stent technology, such as in-stent restenosis and stent thrombosis, while maintaining the prime requirements on biocompatibility, biodegradability, and mechanical behavior. This paper provides an overview of the existing stent types, their functionality, materials, and manufacturing conditions demonstrating the still huge potential for the development of promising stent solutions.
Author(s)
Beshchasna, Natalia  
Fraunhofer-Institut für Keramische Technologien und Systeme IKTS  
Saqib, Muhammad  
Fraunhofer-Institut für Keramische Technologien und Systeme IKTS  
Kraskiewicz, Honorata
Balton Sp. o.o.
Wasyluk, Lukasz
Balton Sp. o.o.
Kuzmin, Oleg
VIP Technologies
Duta, Oana Cristina
Polytechnische Universität Bukarest
Ficai, Denisa
Polytechnische Universität Bukarest
Ghizdavet, Zeno
Polytechnische Universität Bukarest
Marin, Alexandru
Polytechnische Universität Bukarest
Ficai, Anton
Polytechnische Universität Bukarest / Academy of Romanian Scientists
Sun, Zhilei
Polytechnische Universität Tomsk
Pichugin, Vladimir F.
Polytechnische Universität Tomsk
Opitz, Jörg  
Fraunhofer-Institut für Keramische Technologien und Systeme IKTS  
Andronescu, Ecaterina
Polytechnische Universität Bukarest / Academy of Romanian Scientists
Journal
Pharmaceutics  
Funder
Bundesministerium für Bildung und Forschung BMBF (Deutschland)  
Open Access
DOI
10.3390/pharmaceutics12040349
Additional link
Full text
Language
English
Fraunhofer-Institut für Keramische Technologien und Systeme IKTS  
Keyword(s)
  • stent

  • stent coating

  • titanium oxynitride coating

  • drug-eluting stent

  • bioresorbable stent stent manufacturing

  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024